Literature DB >> 28283184

Angiotensin-(1-7) regulates angiotensin II-induced matrix metalloproteinase-8 in vascular smooth muscle cells.

Feng Zhang1, Sufang Li2, Junxian Song2, Jun Liu2, Yuxia Cui2, Hong Chen3.   

Abstract

BACKGROUND AND AIMS: Angiotensin II (Ang II) is a bioactive peptide that is related to cardiovascular disease such as atherosclerosis, whereas angiotensin-(1-7) (Ang-(1-7)) is a counter-regulator of angiotensin II, which protects against cardiovascular disease. Matrix metalloproteinase 8 (MMP-8) is thought to participate in plaque destabilization though degradation of extracellular matrix, improving the development of atherosclerosis. Whether Ang-(1-7) modulates Ang II-induced MMP-8 remains unclear. In this study, we investigated the effect of Ang-(1-7) on Ang II-induced MMP-8 expression in smooth muscle cells.
METHODS: Smooth muscle cells were treated with Ang II, Ang-(1-7) and their antagonists. In addition, ApoE knockout mice were fed a high fat diet and subcutaneously injected with Ang II, Ang-(1-7), Ang II+Ang-(1-7) (±A779).
RESULTS: We found that Ang II increased MMP-8 mRNA and protein expression in vascular smooth muscle cells, while Ang-(1-7) alone had no effect. However, Ang-(1-7) inhibited Ang II-induced MMP-8 expression. The inhibitory effect of Ang-(1-7) could be abolished by the competitive antagonist of Ang-(1-7) at the MAS receptor. Furthermore, Ang II induced p38 MAPK activation, and this was inhibited by the treatment of Ang-(1-7). Ang II-induced MMP-8 expression could be attenuated by the p38 MAPK inhibitor SB203580. Ang-(1-7) also significantly suppressed Ang II-induced MMP-8 in both atherosclerotic plaques and serum in ApoE-/- mice. The atherosclerotic plaques in mice treated with Ang-(1-7) and Ang II appeared to be more stable with more type I collagen contents than those in mice treated with Ang II.
CONCLUSIONS: Our results suggest that Ang-(1-7) plays an important role in protecting against atherosclerosis via counter-regulation of Ang II-induced MMP-8.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiotensin; Matrix metalloproteinase-8; Smooth muscle cell

Mesh:

Substances:

Year:  2017        PMID: 28283184     DOI: 10.1016/j.atherosclerosis.2017.02.012

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

Review 1.  Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis.

Authors:  Fernando Pedro de Souza-Neto; Melissa Carvalho Santuchi; Mario de Morais E Silva; Maria José Campagnole-Santos; Rafaela Fernandes da Silva
Journal:  Curr Hypertens Rep       Date:  2018-03-14       Impact factor: 5.369

2.  Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40.

Authors:  Hui Zhang; Wenping Zhou; Chang Cao; Wenjing Zhang; Gangqiong Liu; Jinying Zhang
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

Review 3.  ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease.

Authors:  Jithin Kuriakose; Augusto C Montezano; Rhian M Touyz
Journal:  Clin Sci (Lond)       Date:  2021-01-29       Impact factor: 6.876

4.  Association of Angiotensin II Type 1 Receptor Agonistic Autoantibodies With Outcomes in Patients With Acute Aortic Dissection.

Authors:  Xiao-Wei Wu; Gang Li; Xiao-Bin Cheng; Min Wang; Liu-Lin Wang; Hai-Hao Wang; Jian-Ye Yang; Xing-Jian Hu
Journal:  JAMA Netw Open       Date:  2021-10-01

Review 5.  Endogenous Vasoactive Peptides and Vascular Aging-Related Diseases.

Authors:  Yao Chen; Yongfen Qi; Weiwei Lu
Journal:  Oxid Med Cell Longev       Date:  2022-10-03       Impact factor: 7.310

6.  Angiotensin (ang) 1-7 inhibits ang II-induced atrial fibrosis through regulating the interaction of proto-oncogene tyrosine-protein kinase Src (c-Src) and Src homology region 2 domain-containing phosphatase-1 (SHP-1)).

Authors:  Li Lu; Li Cao; Yihao Liu; Yunlin Chen; Jinqi Fan; Yuehui Yin
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.